Business Description
Ascentage Pharma Group International
ISIN : KYG0519B1023
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.6 | |||||
Equity-to-Asset | 0.02 | |||||
Debt-to-Equity | 29.72 | |||||
Debt-to-EBITDA | -6.63 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -0.97 | |||||
Beneish M-Score | -1.6 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 133 | |||||
3-Year EBITDA Growth Rate | 6.5 | |||||
3-Year EPS without NRI Growth Rate | 1 | |||||
3-Year FCF Growth Rate | 13.8 | |||||
3-Year Book Growth Rate | -62.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 83.54 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 57.52 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 80.81 | |||||
9-Day RSI | 76.5 | |||||
14-Day RSI | 73.54 | |||||
6-1 Month Momentum % | 43.75 | |||||
12-1 Month Momentum % | 41.54 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.44 | |||||
Quick Ratio | 1.42 | |||||
Cash Ratio | 1.14 | |||||
Days Inventory | 137.88 | |||||
Days Sales Outstanding | 38.69 | |||||
Days Payable | 973.53 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.7 | |||||
Shareholder Yield % | -3.92 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 96.94 | |||||
Operating Margin % | -36.92 | |||||
Net Margin % | -40.77 | |||||
FCF Margin % | -87.09 | |||||
ROE % | -101.97 | |||||
ROA % | -13.1 | |||||
ROIC % | -18.26 | |||||
3-Year ROIIC % | -13.36 | |||||
ROC (Joel Greenblatt) % | -39.4 | |||||
ROCE % | -15.23 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 12.2 | |||||
PB Ratio | 176.32 | |||||
EV-to-EBIT | -41.55 | |||||
EV-to-EBITDA | -45.42 | |||||
EV-to-Revenue | 13.82 | |||||
EV-to-FCF | -15.71 | |||||
Earnings Yield (Greenblatt) % | -2.41 | |||||
FCF Yield % | -6.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ascentage Pharma Group International Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 115.667 | ||
EPS (TTM) (€) | -0.162 | ||
Beta | 0.08 | ||
Volatility % | 65.44 | ||
14-Day RSI | 73.54 | ||
14-Day ATR (€) | 0.109791 | ||
20-Day SMA (€) | 4.022 | ||
12-1 Month Momentum % | 41.54 | ||
52-Week Range (€) | 1.86 - 4.58 | ||
Shares Outstanding (Mil) | 314.65 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ascentage Pharma Group International Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ascentage Pharma Group International Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ascentage Pharma Group International Frequently Asked Questions
What is Ascentage Pharma Group International(FRA:36X)'s stock price today?
When is next earnings date of Ascentage Pharma Group International(FRA:36X)?
Does Ascentage Pharma Group International(FRA:36X) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |